Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA ...
The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the company said Friday ...
Welcome to 2024's regulatory tracker for Fierce Pharma. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new indications.
Geron's CEO said the company anticipates a peak market potential of $1.2 billion in the US and some key EU countries by 2030. In March, by a 12-to-2 margin, the FDA adcomm panel voted in favor of ...
The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus.
Gene therapy is a new medical breakthrough which has, in reality, been several decades in the making. The concept was first suggested 50 years ago as a possibility for targeted treatments, but it ...
On May 31, 2024, Moderna announced that the FDA has approved its respiratory syncytial virus vaccine (“RSV”), mRESVIA (mRNA-1345). The vaccine was designed to protect adults from lower ...
Wednesday, the FDA granted accelerated approval to Eli Lilly And Co’s (NYSE:LLY) selpercatinib (Retevmo) for pediatric patients two years of age and older with the following: Advanced or ...